您现在的位置: 首页> 研究主题> 神经节苷脂GM1

神经节苷脂GM1

神经节苷脂GM1的相关文献在1997年到2021年内共计81篇,主要集中在神经病学与精神病学、基础医学、儿科学 等领域,其中期刊论文79篇、会议论文1篇、专利文献143326篇;相关期刊61种,包括中国应用生理学杂志、中国急救医学、中风与神经疾病杂志等; 相关会议1种,包括第二十一届全国儿科药学学术会议暨第二届全国儿科中青年药师论文报告会等;神经节苷脂GM1的相关文献由263位作者贡献,包括胡志兵、臧召霞、陆雪芬等。

神经节苷脂GM1—发文量

期刊论文>

论文:79 占比:0.06%

会议论文>

论文:1 占比:0.00%

专利文献>

论文:143326 占比:99.94%

总计:143406篇

神经节苷脂GM1—发文趋势图

神经节苷脂GM1

-研究学者

  • 胡志兵
  • 臧召霞
  • 陆雪芬
  • 侯燕明
  • 刘卫东
  • 刘家浩
  • 刘志强
  • 刘景晶
  • 刘洪付
  • 刘蛟
  • 期刊论文
  • 会议论文
  • 专利文献

搜索

排序:

年份

    • 刘丹; 刘敬臣
    • 摘要: 目的:探讨神经节苷脂(GM-1)抑制罗哌卡因诱导神经母细胞瘤细胞(SH-SY5Y)发生焦亡的神经保护作用及分子机制.方法:将对数生长期SH-SY5Y细胞随机分为对照组(C组):无罗哌卡因或GM-1干预;GM-1预处理组(G组):SH-SY5Y细胞中加入5 μmol/L的GM-1培养24h;GM-1预处理组(G+R组):GM-1预处理24h后,SH-SY5Y细胞中加入1.5mmol/L的罗哌卡因培养24 h;罗哌卡因组(R组):SH-SY5Y细胞中加入1.5 mmol/L的罗哌卡因培养24 h.分别通过MTT法测定细胞活力、TUNEL染色法检测细胞凋亡、酶联免疫吸附测定法检测细胞上清炎症因子白细胞介素(IL)-1β、IL-18含量、免疫荧光法和蛋白印迹法检测焦亡相关因子Gasdermin D(GSDMD)、Nod样受体蛋白3(NLRP3)、半胱氨酸天冬氨酸酶-1(caspase-1)表达差异.结果:与C组比较,G+R组和R组SH-SY5Y细胞存活率明显降低(P<0.05),细胞凋亡率、IL-1β、IL-18含量及焦亡相关蛋白(GSDMD、NLRP3、caspase-1)表达水平升高(P<0.05),G组细胞凋亡率显著增加(P<0.05),其他指标无显著变化(P>0.05);与G组相比,G+R组和R组上述各指标均有统计学差异(P<0.05);与R组相比,G+R组上述指标变化均显著改善(P<0.05).结论:GM-1可通过减少GSDMD、NLRP3和caspase-1表达从而减轻焦亡,有效抑制罗哌卡因所致SH-SY5Y细胞的神经毒性作用.
    • 李建雄; 李艳; 马汉伟; 石红; 连佛彦; 王君棪; 白银亮
    • 摘要: Objective To evaluate the effects of ganglioside GM1 on hypoxic ischemic brain damage (HIBD) in neonatal rats and on the expression of potassium-chloride cotransporter 2 (KCC2) in hippocampus.Methods Seven-day-old Sprague-Dawley (SD) rats (n=72) were randomly divided into a sham group,an HIBD group and a ganglioside GM1 group.Each group was further divided into a 3 d subgroup and a 21 d subgroup according to the different detection index (n=12).Rat HIBD models were prepared according the Rice-Vannucci method.After HIBD,the ganglioside GM1 group was given ganglioside GM1 20 mg/ (kg ·d) by intraperitoneal injection for 3 d continuously.2-,3-,5-triphenyltetrazolium chloride (TTC) was preformed to evaluate the area of cerebral infarction of HIBD in each 3 d subgroup.Spontaneous activity recorder was used to observe the locomotor activity of the rats in the 21 d subgroups.Morris water maze test was conducted for assessment of rats' learning and memory abilities in the 21 d subgroups.Western blot analysis was employed to determine the alterations in KCC2 expression in hippocampus in all the 3 d and 21 d subgroups.Results Compared with the HIBD group (28.6%±5.2%),the ratio of cerebral infarction volume in the ganglioside GM1 group (11.3%±2.4%) was significantly reduced (P<0.05).Compared with the HIBD group (289.6±61.3),the number of locomotor activities within 2 h in the ganglioside GM1 group (412.1±66.8) was significantly increased (P<0.05).Compared with the HIBD group,the escape latency was significantly reduced,but the percentage time of target quadrant and the number of crossing the platform were significantly increased in the ganglioside GM1 group (P<0.05).Three days and 21 days after HIBD,the expression of KCC2 in the ganglioside GM1 group was significantly higher than that in the HIBD group (P<0.05).Conclusion Ganglioside GM1 may have a significant protective effect on HIBD in neonatal rats,and its mechanism may be related to regulation of the expression of KCC2 in hippocampus.%目的 探讨神经节苷脂GM1对新生大鼠缺氧缺血性脑损伤(HIBD)的作用及对海马K+-Cl-协同转运蛋白2(KCC2)表达的影响. 方法 72只7d龄新生SD大鼠按随机数字表法分为假手术组、HIBD模型组和神经节苷脂GM1组,各组又依据检测指标的不同分为3d亚组和21d亚组,每亚组12只.后2组参考Rice-Vannucci法建立HIBD模型,神经节苷脂GM1组于造模后即刻予神经节苷脂GM1 20 mg/(kg·d)腹腔注射,连续给药3d.采用2,3,5-三苯基氯化四氮唑(TTC)法检测各3d亚组脑梗死体积比率,自主活动记录仪观察记录各21d亚组的自主活动情况,Morris水迷宫实验评估各21d亚组的学习记忆能力,Western blotting检测各3d、21d亚组海马组织KCC2蛋白的表达. 结果 与HIBD模型组[(28.6±5.2)%]相比,神经节苷脂GM1组脑梗死体积比[(11.3±2.4)%]明显降低,差异有统计学意义(P<0.05).与HIBD模型组[(289.6±61.3)次]比较,神经节苷脂GM1组2h内自主活动数[(412.1±66.8)次]明显增加,差异有统计学意义(P<0.05).与HIBD模型组比较,神经节苷脂GM1组逃逸潜伏期明显降低,穿越原平台次数和目标象限停留时间百分比均明显升高,差异均有统计学意义(P<0.05).神经节苷脂GM1组3d、21d亚组海马组织KCC2蛋白的表达较相应时间点的HIBD模型组均明显增高,差异均有统计学意义(P<0.05). 结论 神经节苷脂GM1对新生大鼠HIBD具有显著保护作用,机制可能与其调节海马KCC2的表达有关.
    • 刘岳鑫; 刘庆; 邓瑞; 张英
    • 摘要: 目的 分析神经节苷脂GM1对脑外伤术后认知功能障碍的疗效.方法 计算机检索Cochrane Library、EBSCO、EMbase、Springer、Ovid、PubMed、CNKI、WanFang Data和CBM,收集神经节苷脂GM1治疗脑外伤术后认知功能障碍的随机对照试验(RCT),同时根据已纳入文章的参考文献查找所需文献,文献检索时间均为从建库至2017年5月.两位研究者独立提取纳入文献资料并评价纳入研究质量,采用Cochrane系统评价推荐软件RevMan5.3进行定量Meta分析.结果 共纳入8篇RCT,纳入患者573例.Meta分析结果显示:5篇文章(353例患者)比较了应用神经节苷脂治疗脑外伤术后认知功能障碍第1个疗程后对MMSE的影响,应用神经节苷脂治疗后的患者MMSE明显高于对照组[MD=3.57,95%CI(1.75,5.40),P<0.01].5篇文章(353例患者)比较了神经节苷脂第二个疗程对MMSE的影响,应用神经节苷脂治疗2个疗程后的患者MMSE明显高于对照组[MD=4.45,95%CI(4.68, 5.21),P<0.01].7篇文章(513例患者)比较了完成神经节苷脂全部疗程后对MMSE的影响,应用神经节苷脂治疗后的患者MMSE明显高于对照组[MD=5.3,95%CI(4.51,608),P<0.01].3篇文章发现研究组患者的总有效率明显高于对照组(P<0.01),[MD=5.11,95%CI(2.39,10.92),P<0.01].1篇文章发现研究组的颅内压、血浆中的IL-6和TNF-α水平均低于对照组,大脑中动脉Vmean及Vmin均大于对照组(P<0.01).结论 现有研究表明,神经节苷脂GM1对脑外伤术后认知功能障碍的疗效明显.%Objective To systematically review the curative effects of monosialoganglioside GM1 (GM1) on postoperative cognitive dysfunction after traumatic brain injury.Methods The randomized controlled trials(RCTs)about curative effect of monosialoganglioside GM1 on postoperative cognitive dysfunction in the patients with craniocerebral trauma were searched in Cochrane library,EBSCO,EMbase,Springer,Ovid,PubMed,CNKI,WanFang Data,and CBM from their inception to May 2017,and the references of the included studies were also retrieved.The data of the included studies was extracted and evaluated by two researchers independently.Then meta-analysis was performed for the results of homogeneous studies by using The Cochrane Collaboration's Software RevMan5.3.Results Eight RCT studies were an-alyzed in our study,including 573 patients.The results of meta-analysis showed that MMSE score after the first course of treatment with GM1 in five articles(including 353 patients)was significantly higher than that in the control group(MD=3.57,95%CI(1.75,5.40),P<0.01).MMSE score after two courses of treatment with GM1 in five articles(353 patients) was significantly superior to that in the control group(MD=4.45,95%CI(4.68,5.21),P<0.01).Meanwhile,MMSE scores in seven articles which finished all courses of treatment(involving 513 patients)were significantly superior to those in the control group(MD=5.3,95%CI(4.51,608),P<0.01).The total effective rate in the study group was significantly higher than that in the control group in three articles(MD=5.11,95%CI(2.39,10.92),P<0.01).In one article,the intracranial pres-sure,IL-6 and TNF-α levels in plasma of the study group were lower than those in the control group,and the Vmean and Vmin of middle cerebral artery were both higher than those in the control group(P<0.01).Conclusion GM1 has signifi-cant therapeutic values in treating postoperative cognitive dysfunction after traumatic brain injury.
    • 刘丽; 张可; 王金春; 曹云鹏
    • 摘要: Objective To investigate the changes of ganglioside GM1 of lipid raft in platelets in patients with Alzheimer''s disease (AD),in order to find an early biomarker for diagnosis of AD.Methods The neurological functions of 42 patients with AD and 45 subjects with normal cognition were evaluated by neuropsychological examinations.Lipid raft was isolated by Optiprep gradient centrifugation and identified by dot blotting.The protein content was measured by using BCA assay,ganglioside GM1 content using colorimetry and dot blotting analysis.Results A white light-scattering band under light illumination located at interface between 25%~30% Optiprep was detectable,which was revealed by dot-blotting.The lipid raft fraction floats within Optiprep gradient fraction 6.The platelet lever of protein in lipid raft was slightly higher in AD group than that in the control group,but there was no statistically significant difference between the two groups (P=0.1494).The platelet lever of ganglioside GM1 in lipid raft was statistically significantly higher in the AD group than that in the control group (P<0.01),but it was not significantly correlated with the age and the scores of MMSE.Conclusion As compared with normal mental state control,the ganglioside GM1 in lipid raft of the platelets in AD group was significantly increased,which may be associated with AD.The altered ganglioside GM1 in lipid raft of the platelets,probably an early biomarker of AD,is of potential value in clinical diagnosis of AD.%目的 研究阿尔茨海默病(AD)患者血小板脂质筏内神经节苷脂GM1含量的变化,寻求一种可能作为辅助诊断AD的早期生物学指标.方法 选择42例AD患者和45例认知功能正常的健康对照者分别进行神经功能评定,采用以Optiprep为介质的密度梯度离心方法分离血小板脂质筏,应用点印迹的方法进行鉴定后,采用BCA法测定血小板脂质筏内蛋白含量,比色法及点印迹定量分析法测定其内神经节苷脂GM1含量.结果 在离心管25%~30% Optiprep溶液界面处可见一条白色的闪亮环带,经点印迹法证实,位于第6层的此白色闪亮环带即为脂质筏.AD组血小板脂质筏内蛋白含量略高于对照组,但差异无统计学意义(P=0.1494).AD组血小板脂质筏内神经节苷脂GM1含量明显高于对照组,差异有统计学意义(P<0.01),但其与年龄、MMSE评分无相关性.结论 AD组患者血小板脂质筏内神经节苷脂GM1含量与对照组相比明显升高,故血小板脂质筏内神经节苷脂GM1含量的改变在AD的诊断中有一定的潜在价值,有望成为一种辅助诊断AD的早期生物学指标.
    • 宋英; 许西西; 丁维; 茅东升
    • 摘要: 目的:研究内源性神经节苷脂对大鼠嗜铬细胞瘤细胞株(PC12)脂多糖(LPS)损伤后的作用及机制.方法:培养PC12细胞,建立LPS损伤模型,采用MTT法检测不同浓度LPS对PC12细胞存活率的改变、葡萄糖神经酰胺合成酶抑制剂D(D-PDMP)耗竭内源性神经节苷脂时LPS对PC12细胞存活率的改变以及添加外源性神经节苷脂GM1后对PC12细胞存活率的保护作用;倒置显微镜和荧光显微镜观察细胞状态;RT-PCR检测NF-κB的相对表达含量.结果:LPS能导致PC12细胞形态学的改变及存活率下降,且随着LPS浓度的增加细胞存活率逐渐降低;神经节苷脂GM1能明显改善LPS所致的细胞形态学以及存活率的改变;工具药D-PDMP耗竭内源性神经节苷脂后,LPS对PCl2细胞的损伤更严重,添加外源性神经节苷脂GM1,细胞形态学及存活率得到明显改善,细胞存活率上升;LPS损伤时细胞内NF-κB含量增加;D-PDMP预先耗竭内源性神经节苷脂时NF-κB含量增加更多;添加外源性神经节苷脂GM1后NF-κB含量降低.结论:内源性神经节苷脂对PC12细胞LPS损伤具有保护作用,可能是通过NF-κB信号通路来发挥作用的.
    • 臧召霞; 朴钟源; 魏亚芬; 殷萍; 刘永丹; 卢冲; 刘志强
    • 摘要: 目的:研究探讨神经节苷脂GM1治疗症状波动的临床疗效。方法选取该院2010年3月—2013年2月收治的46例的患者作为研究对象,所有患者均在长期服左旋多巴等治疗药物后有症状波动的情况发生。在原有治疗的基础上给予患者神经节苷脂GM1静脉滴注治疗。对患者治疗期间的运动情况、日常生活能力以及治疗结束后病症的临床改善情况,不良反应的发生情况等进行评价。结果该组46例帕金森氏病患者治疗前的UPDRS运动评分和日常生活能力评分平均得分分别为(35.8±10.7)分、(30.2±11.9)分。治疗期间的第2周、第3周、第4周患者的平均运动评分分别为(23.3±8.3)分、(22.7±7.9)分、(22.3±8.4)分;日常生活能力的平均评分分别是(21.1±9.8)分、(20.6±9.4)分、(20.5±9.1)分。患者治疗期间的两组UPDRS评分与治疗前得分之间的比较均有显著差异有统计学意义(P<0.05)。但是各周相同比较项目之间的评分并无显著差异。治疗4周后,患者显著改善13例,改善20例,稍有改善9例,无效4例,总治疗有效率为91.3%。2例患者出现恶心呕吐的不良反应,但程度轻微,不加干预可自行消失。结论神经节苷脂GM1具有辅助帕金森氏病治疗的作用,尤其在患者长期使用左旋多巴出现症状波动的情况下,加用神经节苷脂GM1能有效改善患者的运动迟缓、日常生活能力降低等情况,提高患者的生存质量。
    • 费立博; 狄佳; 聂时南
    • 摘要: 目的 通过GCS评分变化评价神经生长因子(NGF)联合神经节苷脂(GM1)对弥漫性轴索损伤(DAI)的疗效.方法 将86例临床诊断为弥漫性轴索损伤的患者随机分为两组,其中治疗组44例,使用NGF和GM1联合治疗;对照组42例,仅使用GM1治疗.两组疗程均20 d,在治疗第1、3、7、20天分别进行GCS评分,6个月后进行随访GOS评分.结果 治疗组患者的GCS评分、GOS评分明显优于对照组(P<0.05).结论 NGF联合GM1治疗弥漫性轴索损伤疗效明显优于仅使用GM1.
    • 艾尔肯
    • 摘要: 目的分析神经节苷脂GM1治疗急性脑梗死的临床疗效.方法将我院收治的66例急性脑梗死患者随机分成两组.对照组32例,根据病情常规予以抗凝、调脂、抗血小板、降纤及降颅压等治疗,如有高血压、糖尿病者给予相应处理,14 d为1个疗程;治疗组34例在对照组常规治疗的基础上,加用神经节甘脂GM1 60 mg+0.9%生理盐水250 mL静脉滴注(1次/d),14 d为1个疗程.结果治疗组总有效率为94.1%,对照组总有效率为74.9%.治疗前两组性别、年龄、病灶大小及发病时治疗时间等方面比较差异无统计学意义(P>0.05);治疗后两组神经功能缺损程度均有改善,而神经节苷脂GM1治疗组疗效显著,两组神经功能缺损程度评分差异有统计学意义(P<0.05).结论神经节苷脂GM1治疗急性脑梗死疗效显著,且安全,临床可以推广使用.
    • 林琳
    • 摘要: 目的 探讨单唾液酸四己糖神经节苷脂(GM1)治疗新生儿缺氧缺血性脑病(HIE)的疗效.方法 将200例HIE患儿随机分为观察组和对照组,每组各100例,各含轻度48例、中度34例和重度18例,均予常规治疗,观察组在此基础上应用GM1治疗,10d为1个疗程.观察和记录临床症状、体征恢复情况和新生儿行为神经测定(NBNA)评分.结果 观察组与对照组的总有效率差异无统计学意义(P=1.83);中、重度观察组的总有效率与相应的对照组比较差异有统计学意义(P=0.02).在治疗后轻、中度观察组的NBNA评分高于相应的对照组,差异有统计学意义(P=0.042,0.005);重度观察组的NBNA评分和对照组相比,差异无统计学意义(P=0.384).结论 GM1治疗对轻、中度HIE疗效好,能促进临床症状恢复,缩短病程,提高治愈率.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号